VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Hepatitis C virus

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
  2. Vaccine Related Pathogen Genes
    1. Core protein (Other)
    2. E1 (Protective antigen)
    3. E2 (Protective antigen)
    4. VP60 (Protective antigen)
  3. Vaccine Information
    1. AdCh3NSmut
  4. References
I. General Information
1. NCBI Taxonomy ID:
11103
2. Disease:
Hepatitis C
3. Introduction
Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States; approximately 3.2 million persons are chronically infected. Although HCV is not efficiently transmitted sexually, persons at risk for infection through injection drug use might seek care in STD treatment facilities, HIV counseling and testing facilities, correctional facilities, drug treatment facilities, and other public health settings where STD and HIV prevention and control services are available.

Sixty to 70% of persons newly infected with HCV typically are usually asymptomatic or have a mild clinical illness. HCV RNA can be detected in blood within 1–3 weeks after exposure. The average time from exposure to antibody to HCV (anti-HCV) seroconversion is 8–9 weeks, and anti-HCV can be detected in >97% of persons by 6 months after exposure. Chronic HCV infection develops in 70%–85% of HCV-infected persons; 60%–70% of chronically infected persons have evidence of active liver disease. The majority of infected persons might not be aware of their infection because they are not clinically ill. However, infected persons serve as a source of transmission to others and are at risk for chronic liver disease or other HCV-related chronic diseases decades after infection.

HCV is most efficiently transmitted through large or repeated percutaneous exposure to infected blood (e.g., through transfusion of blood from unscreened donors or through use of injecting drugs). Although much less frequent, occupational, perinatal, and sexual exposures also can result in transmission of HCV (CDC - Hepatitis C).
1. Core protein
  • Gene Name : Core protein
  • Sequence Strain (Species/Organism) : Hepatitis C virus
  • NCBI Protein GI : 349623451
  • Other Database IDs : CDD:144947
  • Taxonomy ID : 11103
  • Gene Strand (Orientation) : ?
  • Protein Name : core
  • Protein Length : 114
  • Protein Note : Hepatitis C virus capsid protein; pfam01543
  • Protein Sequence : Show Sequence
    >gi|349623451|gb|AEQ03276.1| core [Hepatitis C virus]
    MSTLPKPQRKTKRNTIRRPQDVKFPGGGQIVGGVYVLPRRGPRLGVRATRKTSERSQPRGRRQPIPKARR
    SEGRSWAQPGYPWPLYGNEGCGWAGWLLSPRGSRPSWGPNDPRR
  • Molecule Role : Other
2. E1
  • Gene Name : E1
  • Sequence Strain (Species/Organism) : Hepatitis C virus
  • NCBI Protein GI : AAO46051
  • Other Database IDs : CDD:110536
    CDD:110557
  • Taxonomy ID : 11103
  • Protein Name : E1
  • Protein pI : 9.58
  • Protein Weight : 5171.61
  • Protein Length : 90
  • Protein Note : genotype: II
  • Protein Sequence : Show Sequence
    >AAO46051.1 E1, partial [Hepacivirus C]
    SMVGNWAKVLIVMLLFAGVDGDTHVTGGRKLTPTHRFASLFSLGPTQK
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : (Zhang et al., 2017)
3. E2
  • Gene Name : E2
  • Sequence Strain (Species/Organism) : Hepatitis C virus
  • NCBI Protein GI : AAB30986
  • Other Database IDs : CDD:110557
  • Taxonomy ID : 11103
  • Protein Name : E2
  • Protein pI : 7.36
  • Protein Weight : 4284.5
  • Protein Length : 82
  • Protein Note : Hepatitis C virus non-structural protein E2/NS1; pfam01560
  • Protein Sequence : Show Sequence
    >AAB30986.1 E2, partial [Hepacivirus C]
    MLLFAGVDGNTYVSGGATSRTTQSLVSFLSPGPQQKIQLV
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : (Pierce et al., 2017)
4. VP60
III. Vaccine Information
1. AdCh3NSmut
a. Type:
Recombinant vector vaccine
b. Status:
Clinical trial
c. Host Species for Licensed Use:
None
d. Antigen
HCV antigen (NS region) (NCT01070407)
e. Vector:
Adenovirus vectors
f. Preparation
2 doses Ad6NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24 (NCT01070407).
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
AdCh3NSmut Is a recombinant vector vaccine containing HCV antigens and is delivered the intramuscular route (NCT01070407).
IV. References
1. CDC - Hepatitis C: Hepatitis C Information for Health Professionals [http://www.cdc.gov/hepatitis/hcv/]
2. Geissler et al., 1997: Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. Journal of immunology (Baltimore, Md. : 1950). 1997; 158(3); 1231-1237. [PubMed: 9013964].
3. Guo et al., 2016: Guo H, Zhu J, Tan Y, Li C, Chen Z, Sun S, Liu G. Self-assembly of virus-like particles of rabbit hemorrhagic disease virus capsid protein expressed in Escherichia coli and their immunogenicity in rabbits. Antiviral research. 2016; 131; 85-91. [PubMed: 27118636].
4. Lang et al., 2012: Lang Kuhs KA, Ginsberg AA, Yan J, Wiseman RW, Khan AS, Sardesai NY, O'Connor DH, Weiner DB. Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses. Molecular therapy : the journal of the American Society of Gene Therapy. 2012; 20(3); 669-678. [PubMed: 21952169].
5. NCT01070407: A Study of a New Candidate Vaccine Against Hepatitis C Virus (HCV) [https://classic.clinicaltrials.gov/ct2/show/NCT01070407]
6. Pierce et al., 2017: Pierce BG, Boucher EN, Piepenbrink KH, Ejemel M, Rapp CA, Thomas WD Jr, Sundberg EJ, Weng Z, Wang Y. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope. Journal of virology. 2017; 91(20); . [PubMed: 28794021].
7. Wu et al., 2016: Wu X, Chen P, Lin H, Hao X, Liang Z. Hepatitis E virus: Current epidemiology and vaccine. Human vaccines & immunotherapeutics. 2016; 12(10); 2603-2610. [PubMed: 27184971].
8. Zhang et al., 2017: Zhang S, Sun F, Ren T, Duan Y, Gu H, Lai C, Wang Z, Zhang P, Wang X, Yang P. Immunogenicity of an influenza virus-vectored vaccine carrying the hepatitis C virus protein epitopes in mice. Antiviral research. 2017; 145; 168-174. [PubMed: 28778831].